Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPhysical Medicine, Rehab & TherapiesAetna Infrared Therapy Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0604

    Infrared Therapy (Clinical Policy Bulletin)

    Customize your policy alerts

    Sign up for Aetna Policy 0604 alerts

    Get alerted when Policy 0604 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This Aetna Clinical Policy Bulletin governs medical necessity and investigational determinations for infrared therapy modalities (including infrared coagulation and low-level infrared/MIRE/Anodyne systems) and indicates covered indications and those considered experimental/investigational for Aetna members.

    Policy Summary
    PayerAetna
    PolicyInfrared Therapy (Clinical Policy Bulletin)
    Policy CodePolicy 0604
    Change TypeNo material change
    Effective DateMar 19, 2002
    Last ReviewSep 8, 2023
    Next Review DateJun 27, 2024
    Key ActionDocument diagnosis codes and clinical justification when billing CPT 46930 for anal dysplasia or grade I–II internal hemorrhoids.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered indications
    29+Experimental indications (partial)
    46930, 97026Example CPT codes
    multiple small studiesSmall/limited evidence
    09/08/2023Last review

    Coverage Criteria for Infrared Therapies

    Medical Necessity - Infrared coagulation

    Covered when ALL of the following are met

    Infrared coagulation covered indications: Infrared coagulation is medically necessary for (1) anal dysplasia; and (2) members with grade I or grade II internal hemorrhoids that are painful or persistently bleeding.

    See Appendix for hemorrhoid grading.

    Evidence summaries by indication

    Evidence summaries and coverage-relevant conclusions by indication

    Ischemic stroke (infrared laser): Small randomized trial (NEST-1) showed improved functional outcomes when initiated within 24 hours; authors recommended larger confirmatory trial.

    Safety similar between groups; mortality and SAE rates not significantly different.

    Peripheral neuropathy / diabetic neuropathy (MIRE/Anodyne): Randomized double-blind trials (e.g., Lavery et al 2008) found no significant differences between active and sham treatment on sensation, nerve conduction, transcutaneous oxygen, pain, or quality of life.

    CMS (2006) concluded infrared devices are not reasonable and necessary for peripheral sensory neuropathy, wounds and ulcers, and related conditions.

    Hemorrhoids (infrared coagulation): RCTs and comparative studies show infrared coagulation is an effective non-surgical option for Grade I-II hemorrhoids; rubber band ligation may be more effective for higher-grade hemorrhoids but associated with more postoperative pain.

    Choice guided by hemorrhoid grade; IRC typically requires about 2 sessions.

    Onychomycosis (laser/light): FDA-cleared lasers can produce temporary cosmetic improvement; randomized and controlled data are limited and inconsistent with uncertain long-term mycological cure.

    Protocols and durability of effect not established.

    Pressure ulcers: Guideline panels concluded evidence is insufficient to support routine use of infrared therapy for pressure ulcers.

    Not recommended for routine use at this time.

    Seasonal Affective Disorder (prevention): Only one small RCT compared bright white light, IR light, and no treatment; both bright and IR light reduced incidence numerically but evidence quality rated very low and imprecise.

    Patient preferences should guide preventive treatment decisions given limited evidence.

    Tendinopathy (PBM): Systematic review of 17 trials (n=835) found PBM alone produced similar pain decreases to other interventions; PBM plus exercise showed greater pain reduction and improved function versus sham plus exercise, but evidence quality ranged from very low to moderate.

    Heterogeneity in PBM parameters and study quality limits conclusions; more robust RCTs needed.

    Traumatic brain injury / other CNS indications: Small case series and early studies report mixed signals (e.g., pulsed transcranial PBM showed promise in small TBI series) but clinical studies are small, heterogenous, and require larger controlled trials.

    Potential risks and heterogeneity of devices/parameters warrant further study.

    Evidence-based summary (no explicit coverage rules in this segment)

    evidence_summary: Evidence across indications is limited, heterogeneous, and often of low or very low quality; small RCTs, uncontrolled studies, case series, and preclinical work predominate. For many indications (SAD prevention, migraine adjunct, TBI cognitive improvement, neuropathic pain, bone regeneration, TMD, tendinopathy), studies report potential signals but are confounded by methodological limitations and small sample sizes.

    No explicit coverage decision stated in this extract.

    Evidence summaries by indication

    Summary of clinical evidence for PBM/IRC by indication:

    Tendinopathy: PBM (red/near-IR) across 17 trials (n=835) showed similar pain decreases to other interventions overall; PBM plus exercise showed greater pain reduction and improved function compared to sham plus exercise; evidence graded very-low-to-moderate; heterogeneity in PBM parameters and study quality limits conclusions.

    More robust RCTs with standardized dosimetry and exercise prescriptions needed.

    Anal HSIL (Infrared Coagulation): Randomized multicenter trial of IRC in HIV-infected adults with 1–3 biopsy-proven HSILs showed higher complete index HSIL clearance at 12 months (62% vs 30%); retrospective cohorts report recurrence but low progression to SCC; device not FDA-approved specifically for anal SIL.

    Studies limited by lesion selection, follow-up, and generalizability.

    Xerostomia: Systematic review identified multiple RCTs with PBMT parameters (790–830 nm, 30–120 mW, energy density <30 J/cm2) associated with improvements; however, trials had heterogeneous protocols and risk of bias.

    Standardized intervention protocols needed.

    The policy lists the infrared glove (e.g., Prolotex Therapy Glove) among interventions considered experimental/investigational. This designation reflects that evidence is insufficient to establish effectiveness of the glove for Raynaud's syndrome or any other indications; therefore use of the glove for these conditions is categorized as investigational and not supported as medically necessary under this CPB.

    A 2006 CMS decision memorandum concluded that the use of infrared devices is not reasonable and necessary for treatment of diabetic and non-diabetic peripheral sensory neuropathy, wounds and ulcers, and related conditions. In practice, this means claims for infrared modalities billed for peripheral neuropathy or similar wound indications are at risk for noncoverage and should be considered unsupported by the available Medicare-level determination.

    Major clinical syntheses in UpToDate do not list infrared therapies as options for migraine management. The absence of infrared in authoritative reviews of acute and preventive migraine care implies that infrared modalities are not established or standard therapies for chronic migraine and should be considered unsupported by current clinical guidance.

    Infrared coagulation (IRC) devices are FDA-cleared for treatment of hemorrhoids and anal warts, but are not FDA-approved specifically for anal squamous intraepithelial lesions (SIL). This regulatory status is noted as relevant when assessing coverage because available IRC studies for anal HSIL are promising but the device’s label does not explicitly include anal SIL.

    Randomized, double-blind trials of low-level infrared therapy (Anodyne MIRE) for diabetic peripheral neuropathy have not shown benefit over sham. For example, a 90-day home-use randomized trial (Lavery et al., 2008) found no significant differences between active and sham groups on measures of sensation, nerve conduction, pain, or quality of life. In addition, the CMS determination (2006) concluded infrared devices are not reasonable and necessary for peripheral sensory neuropathy, supporting the view that MIRE lacks demonstrated clinical benefit for diabetic neuropathy.

    Monochromatic infrared energy (MIRE) and similar low-level infrared devices have not demonstrated superiority to sham control in randomized trials. Several double-blind, sham-controlled studies (including Lavery et al. 2008 and Franzen‑Korzendorfer et al. 2008) reported no significant differences between active and sham treatment for sensation, transcutaneous oxygen, pain, or related outcomes, indicating lack of consistent efficacy versus placebo.

    For indications supported only by small, low-quality trials or heterogeneous early studies (for example, preventive light therapy for seasonal affective disorder and PBM for tendinopathy), the available evidence is insufficient to establish effectiveness. Systematic reviews identify high risk of bias, very small sample sizes, and imprecision in effect estimates, so these indications lack robust data to support coverage as medically necessary.

    Coding and Billing Guidance

    Covered CPT Codes (when selection criteria met)CPTCovered
    46930Destruction of internal hemorrhoid(s), by thermal energy (eg, infrared coagulation, cautery, radiofrequency).
    CPT Codes (modalities referenced)CPT
    97026Application of a modality to one or more areas; infrared.
    HCPCS codes not covered for indications listed in the CPBHCPCSNot Covered
    A4639Replacement pad for infrared heating pad system, each.
    E0221Infrared heating pad system.
    ICD-10 Codes covered if selection criteria are metICD-10Covered
    K62.82Dysplasia of anus.
    K64.0First degree hemorrhoids.
    K64.1Second degree hemorrhoids.
    ICD-10 Codes not covered for indications listed in the CPB (not all-inclusive)ICD-10Not Covered
    B35.1Tinea unguium [onychomycosis].
    I73.00Raynaud's syndrome.
    G43.001Migraine codes (example range referenced).
    E08.00Diabetes mellitus (example range referenced).
    Study inclusion severity/time thresholds (examples)
    Ischemic stroke trial timingNEST-1 enrolled ischemic stroke patients treated within 24 hours of symptom onset (improved functional outcomes when initiated within 24 hours).
    MIRE / Anodyne home dosing (example)Anodyne units used daily at home for 40 minutes per day for 90 days in Lavery et al (randomized trial).
    Leonard ATS trial dosing patternLeonard et al (2004) treated lower extremities over 2 weeks (sham or active) then both received active treatments for an additional 2 weeks; improvement noted after 6 and 12 treatments in a subset.

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior Authorization / Code–Coverage Linking

    Prior authorization may be required and coverage depends on matching billed codes to the policy indications. CPT 46930 (Destruction of internal hemorrhoid(s) by thermal energy, e.g., infrared coagulation) is covered when the selection criteria for anal dysplasia (biopsy-proven HSIL) or Grade I–II internal hemorrhoids are met. Low-level infrared therapy codes (e.g., 97026, Anodyne/MIRE descriptors, and related HCPCS such as E0221, A4639) are not covered for indications listed as investigational or non-covered in this policy.

    • Covered CPT when criteria met: 46930 (destruction of internal hemorrhoid(s) by thermal energy — IRC)
    • Common non-covered/experimental descriptors: 97026 (application of infrared), Anodyne/MIRE devices — no specific CPT; HCPCS: E0221, A4639
    Denial Risk

    CMS Noncoverage Finding (2006)

    A 2006 CMS decision memorandum concluded there is sufficient evidence that infrared devices are not reasonable and necessary for treatment of diabetic and non‑diabetic peripheral sensory neuropathy, wounds and ulcers, and similar related conditions (including associated pain). Plans and prior‑authorization processes should reflect this CMS noncoverage finding when adjudicating claims for these indications.

    Background and Evidence Context

    Low-level infrared therapy (MIRE) delivers single-wavelength infrared energy via flexible pads containing multiple infrared-emitting diodes (commonly 60 diodes per pad). The modality is proposed to increase nitric oxide release from hemoglobin, with the intended downstream effects of vasodilation, reduced swelling and improved microcirculation; the Anodyne Therapy System is an example of such a device.

    Key points about MIRE / low-level infrared therapy: it is a low-energy infrared modality delivered by diode-containing pads applied to the skin, often promoted for wound healing and peripheral neuropathy. The mechanisms cited include purported nitric-oxide–mediated increases in circulation. Meta-analyses and randomized trials have not demonstrated consistent benefit for chronic non-healing wounds or neuropathy, and overall evidence is limited.

    Infrared coagulation — definition and CPT link
    DefinitionInfrared coagulation (IRC): destruction of internal hemorrhoid(s) by thermal energy; procedure described in CPT 46930 (destruction of internal hemorrhoid(s) by thermal energy, e.g., infrared coagulation).
    Typical applicationOffice-based application of a short pulse of infrared irradiation (approx. 1.5 seconds) to produce tissue coagulation and allow debridement, used for hemorrhoids and anal lesions.
    Coding link

    Key Definitions and Hemorrhoid Grading

    Grade I hemorrhoid
    DefinitionGrade I hemorrhoid: Bleeding without prolapse.
    Typical relevanceGrade I hemorrhoids are among those for which infrared coagulation may be considered when painful or persistently bleeding (see coverage criteria).
    Appendix noteInfrared coagulation usually requires 2 sessions to eradicate the hemorrhoids.
    Grade II hemorrhoid
    DefinitionGrade II hemorrhoid: Prolapse with spontaneous reduction.
    Typical relevanceGrade II hemorrhoids are included among hemorrhoid grades referenced in IRC coverage criteria when painful or persistently bleeding.

    Revision History

    2023-09-08policy_reviewLatest

    Policy last reviewed on 09/08/2023.

    2002-03-19effective_date

    Policy effective date established as 03/19/2002.

    2024-06-27next_scheduled_review

    Next scheduled policy review set for 06/27/2024.

    Policy Summary
    PayerAetna
    PolicyInfrared Therapy (Clinical Policy Bulletin)
    Policy CodePolicy 0604
    Change TypeNo material change
    Effective DateMar 19, 2002
    Last ReviewSep 8, 2023
    Next Review DateJun 27, 2024
    Key ActionDocument diagnosis codes and clinical justification when billing CPT 46930 for anal dysplasia or grade I–II internal hemorrhoids.
    SourceLink
    On This Page
    Coverage Criteria for Infrared TherapiesCoding and Billing GuidanceProvider Actions, Prior Authorization & DocumentationBackground and Evidence ContextKey Definitions and Hemorrhoid GradingRevision History
    Calcaneal tendon injury (preclinical): Animal studies demonstrate PBMT can reduce inflammatory markers and accelerate repair in tendon models; clinical translation requires human trials.

    Evidence primarily from animal models.

    Traumatic brain injury / TBI (transcranial PBM): Case-series and small studies report improvements in neuropsychological scores and regional cerebral blood flow after pulsed transcranial PBM; larger controlled studies are required.

    Preliminary and heterogenous clinical data.

    Hemorrhoids (IRC): Appendix notes IRC usually requires about 2 sessions to eradicate hemorrhoids and internal hemorrhoid grades I–IV are provided for context; IRC is an established non-surgical option for early grades.

    Device FDA-cleared for hemorrhoids; choice vs RBL guided by grade and symptomatology.

    • CMS (2006): infrared devices not reasonable/necessary for peripheral neuropathy, wounds, ulcers and similar conditions
    Prior Authorization

    Prior Authorization Recommended for Experimental IR / PBM Applications

    Prior authorization is recommended for experimental or investigational applications of infrared radiation (IR) or photobiomodulation (PBM), such as transcranial pulsed PBM (tPBM) for traumatic brain injury or other neurologic indications, until larger controlled studies demonstrate safety and effectiveness.

    • Experimental/Investigational examples: transcranial pulsed PBM (tPBMT) for TBI, Anodyne/MIRE for neuropathy, other off‑label PBM uses
    Documentation Required

    Prior Authorization Considerations for IRC (Anal Dysplasia / HSIL)

    For infrared coagulation (IRC) for anal HSIL, prior authorization/medical necessity review should expect documentation that supports the indication and procedure: biopsy‑proven anal HSIL (HGAIN/AIN II/III), high‑resolution anoscopy (HRA) findings, description of the index lesion(s), treatment plan, and scheduled follow‑up (e.g., HRA at regular intervals).

    • Required documentation: biopsy-proven HSIL (index lesion[s])
    • Procedural documentation: HRA findings, location/size/number of lesions, IRC treatment details
    • Follow-up: planned surveillance and biopsy strategy (e.g., HRA and biopsies per guideline or study protocol)
    Documentation Required

    Documentation for Covered Coagulation (Hemorrhoids / Anal Dysplasia)

    When IRC is billed for coagulation of hemorrhoids using CPT 46930, retain documentation demonstrating the covered diagnosis (e.g., K62.82 for anal dysplasia or K64.0–K64.1 for 1st–2nd degree hemorrhoids), treatment rationale, and that alternative, established non-surgical therapies were considered where appropriate (for hemorrhoids — e.g., rubber band ligation).

    • Diagnostic ICD-10s supporting coverage: K62.82 (dysplasia of anus); K64.0–K64.1 (first and second degree hemorrhoids)
    • Sequencing note: consider/summarize prior non-surgical treatments (rubber band ligation, topical measures) when applicable
    Documentation Required

    Recommended Outcome Measures to Document

    Trials and studies vary in reported outcome measures; when submitting clinical evidence or prior‑authorization materials, include relevant objective outcome measures where available: vibration perception thresholds (VPT), Semmes‑Weinstein monofilament testing, nerve conduction studies, standardized neurologic/functional scales (e.g., NIHSS, mRS) or lesion‑clearance endpoints for IRC (complete index HSIL clearance at specified follow‑up).

    • Peripheral neuropathy outcomes: VPT, SWM (monofilaments), nerve conduction studies
    • Stroke/TBI/neurologic studies: NIHSS, mRS, functional scales, SPECT measures (when applicable)
    • IRC for HSIL: index lesion clearance at defined time points (e.g., 12 months)
    Documentation Required

    Device and Measurement Documentation

    Device and measurement details affect interpretation of results and are expected in records supporting medical necessity. Document device make/model, settings (power, wavelength, pulse parameters), treatment duration, distance/spot size, and test conditions (e.g., instrument model for thermometry, tester identity) that could influence outcome measures.

    • Record device specifics: manufacturer/model, wavelength, power density, pulse frequency, duration/number of treatments
    • Measurement context: instrument model, distance-to-spot, emissivity, tester ID for temperature/neurologic measures
    Documentation Required

    Studies Report Requirement for Biopsy-Proven HSIL and Structured Follow-up

    Studies of IRC for anal HSIL typically require biopsy‑proven HSIL for enrollment and report structured follow‑up with HRA and biopsy to document index lesion clearance or recurrence. Prior‑authorization and medical records should mirror these evidentiary expectations when asserting medical necessity for IRC.

    • Evidence expectation: biopsy-proven HSIL (index lesion[s]) prior to IRC
    • Follow-up evidence: HRA and biopsies per protocol to demonstrate clearance or recurrence
    Note

    Retain Documentation per Aetna Clinical Policy Bulletin Guidance

    Providers should retain complete clinical documentation to support medical necessity determinations in accordance with Aetna Clinical Policy Bulletin guidance. The CPB provides the policy framework; however, plan‑specific provisions (benefits, prior‑authorization processes, and coverage exceptions) govern payment decisions.

    • Retain all records supporting indication, procedure, device details, outcomes, and prior treatments
    • Note: CPB guides benefit administration but payer plan provisions ultimately determine coverage
    Step Therapy

    Consider Established Alternatives and Note Guideline Variability

    When IR is considered for prevention or non‑treatment indications (e.g., prevention of seasonal affective disorder or neuropathy), prefer established preventive or therapeutic alternatives with stronger evidence. Guideline recommendations vary and multiple treatment modalities exist for conditions such as SAD and anal HSIL; document rationale when selecting IR over other options.

    • Clinical preference: use established preventive/therapeutic options before experimental IR uses
    • Guideline variability: note that recommendations differ across societies for anal HSIL management; provide justification when deviating
    Relevant procedure code: CPT 46930 (destruction of internal hemorrhoid(s) by thermal energy).
    Laser/light therapy for onychomycosis — definition and FDA context
    DefinitionLaser/light therapy for onychomycosis: use of Nd:YAG, diode, or infrared lasers applied to the nail unit to produce thermal or photobiomodulatory effects, intended to improve nail appearance and/or eradicate fungus.
    FDA contextSince 2010 FDA has cleared laser systems as capable of producing a temporary increase in clear nails, but long-term mycological cure and standardized protocols are lacking.
    Evidence noteRandomized and controlled data are limited and inconsistent; routine use not recommended until more robust data available.
    R/NIR-IT — definition and experimental uses
    DefinitionR/NIR-IT (red/near-infrared irradiation therapy): application of red to near-infrared wavelengths (reported here as ~630–1000 nm) used experimentally for CNS and retinal conditions and other indications.
    Experimental usesStudied for retinal degeneration, white matter/CNS injury, stroke, Parkinson's disease, and transcranial applications for TBI; evidence heterogeneous and limited by parameter variability.
    Evidence considerationsOutcomes and penetration depend on specification of treatment parameters; clinical benefit remains unconfirmed in many CNS indications.
    Infrared (IR) and Photobiomodulation (PBM) — wavelength ranges and note
    IR wavelength spanInfrared (IR) radiation: described as wavelengths between ~760 and 100,000 nm in the source.
    PBM wavelength rangePhotobiomodulation (PBM) / LLLT generally employs red and near-IR wavelengths (reported in the source as 100 to 600 nm, noting a textual inconsistency), with therapeutic effects dependent on fluence, irradiance, timing, pulsing, and wavelength.
    Parameter dependenceTherapeutic effects depend on fluence, irradiance, treatment timing and repetition, pulsing, and wavelength; standardized dosimetry lacking across studies.
    Transcranial near-infrared laser therapy — definition and intended use
    DefinitionTranscranial near-infrared laser therapy (tNiRLT / tPBMT): application of near-infrared or red light transcranially using LED or laser devices aiming to improve cognitive or neurologic function (e.g., after TBI); parameters vary by study.
    Intended use/examplesStudied to improve neuropsychological test scores and regional cerebral blood flow in small case-series and pilot studies of chronic TBI; larger controlled trials needed.
    Device/parameter variabilityStudies use varied pad configurations, LED/laser power outputs, dosing durations, and pulsing frequencies; clinical effects depend on these variables.
    Infrared coagulation (IRC) — application and tissue effect
    DefinitionInfrared coagulation (IRC): an office-based application of a short pulse of infrared irradiation (approx. 1.5 seconds) applied to dysplastic anal or hemorrhoidal epithelium producing tissue destruction to a depth of approximately 1.5 mm.
    Procedure detailsCoagulated tissue may be debrided with biopsy forceps; possible complications include immediate and delayed bleeding and infection.
    Regulatory noteDevice is FDA-approved for treatment of hemorrhoids and anal warts but not specifically approved for anal squamous intraepithelial lesions (SIL).
    Photobiomodulation (PBM) — therapeutic definition and parameters
    DefinitionPhotobiomodulation (PBM): therapeutic use of red or near-infrared light (lasers or LEDs) intended to reduce pain, inflammation, or promote tissue repair; parameters (wavelength, power, fluence, dosing schedule) vary widely across studies.
    Typical parameters (examples)Xerostomia trials used wavelengths 790–830 nm, power 30–120 mW, and energy density <30 J/cm2; tendinopathy and animal studies report diverse parameters and dosing regimens.
    Intended effectsReported intended effects include pain reduction, decreased inflammation, accelerated tissue repair, and improved function, but evidence quality and standardization are limited.
    Treatment note
    Non-surgical options such as infrared coagulation or rubber band ligation are alternatives for early-stage (Grade I–II) hemorrhoids.
    Grade III hemorrhoid
    DefinitionGrade III hemorrhoid: Prolapse requiring manual reduction.
    Clinical noteRubber band ligation is generally more effective than IRC for higher-grade hemorrhoids (e.g., Grade III), though associated with more postoperative pain.
    ContextHemorrhoid grade classification guides choice among non-surgical and surgical options.
    Grade IV hemorrhoid
    DefinitionGrade IV hemorrhoid: Incarcerated, irreducible prolapse.
    Clinical relevanceGrade IV hemorrhoids typically require surgical management rather than office-based IRC; classification informs treatment selection.
    Appendix referenceInternal hemorrhoid grading provided for clinical context in the policy appendix.
    MIRE / low-level infrared therapy (quick reference)
    DefinitionMIRE / low-level infrared therapy: low-energy infrared modality delivered by flexible pads containing multiple infrared-emitting diodes (example: Anodyne Therapy System).
    Proposed mechanismThought to stimulate nitric oxide release from hemoglobin, dilating blood vessels and increasing circulation.
    Clinical evidence noteRandomized trials and meta-analyses have not consistently demonstrated benefit for diabetic neuropathy or chronic non-healing wounds; some RCTs show no difference versus sham.
    Infrared coagulation (IRC) — quick reference
    DefinitionInfrared coagulation (IRC): destruction of internal hemorrhoid(s) by thermal energy; office-based short pulse (~1.5 sec) application producing tissue coagulation allowing debridement.
    Regulatory noteDevice is FDA-approved for hemorrhoids and anal warts but not specifically for anal squamous intraepithelial lesions (SIL).
    Coding linkProcedure commonly billed with CPT 46930 (destruction of internal hemorrhoid(s) by thermal energy).